DAMONA Pharmaceuticals was recently highlighted in a news article, prepared by Ben Gane, for the University of Toronto. This article highlights the creation of Damona by CAMH (the Centre of Addiction and Mental Health in Toronto) and Dr. Etienne Sibille.
In this article, you can learn about the company’s achievements that have attracted substantial investment to further AC-101 for the treatment of cognitive dysfunctions in depression.
Our novel molecules enter the brain, activate the target, and alleviate the cognitive deficits caused by chronic stress or aging, while also reversing the brain cell damage associated with these conditions
Dr. Etienne Sibille, CEO and CSO of Damona, Senior Scientist at CAMH and Professor in Psychiatry, and Pharmacology/Toxicolgy at UofT.
DAMONA is the culmination of work that was both philanthropically and externally funded (including support from National Institutes of Health, Canadian Institutes of Health Research, the Weston Brain Institute, Toronto Innovation Acceleration Partners, the Ontario Brain Institute, and Family Offices), and throughout institutionally supported
says Dr. Aristotle Voineskos, Vice President of Research and Director of the Campbell Family Mental Health Research Institute at CAMH, Professor in Psychiatry at UofT
The article also points how DAMONA fosters unique growth trajectory for early career scientists such as Dr. Thomas Prevot, Director of Operation, Research and Development in Damona, scientist at CAMH and assistant professor in the Department of Psychiatry of the University of Toronto.